Abstract
Constitutive activation of the JAK/STAT3 pathway is a major contributor to oncogenesis. In the present study, structure–activity relationship (SAR) studies with five cucurbitacin (Cuc) analogs, A, B, E, I, and Q, led to the discovery of Cuc Q, which inhibits the activation of STAT3 but not JAK2; Cuc A which inhibits JAK2 but not STAT3 activation; and Cuc B, E, and I, which inhibit the activation of both. Furthermore, these SAR studies demonstrated that conversion of the C3 carbonyl of the cucurbitacins to a hydroxyl results in loss of anti-JAK2 activity, whereas addition of a hydroxyl group to C11 of the cucurbitacins results in loss of anti-STAT3 activity. Cuc Q inhibits selectively the activation of STAT3 and induces apoptosis without inhibition of JAK2, Src, Akt, Erk, or JNK activation. Furthermore, Cuc Q induces apoptosis more potently in human and murine tumors that contain constitutively activated STAT3 (i.e., A549, MDA-MB-435, and v-Src/NIH 3T3) as compared to those that do not (i.e., H-Ras/NIH 3T3, MDA-MB-453, and NIH 3T3 cells). Finally, in a nude mouse tumor xenograft model, Cuc Q, but not Cuc A, suppresses tumor growth indicating that JAK2 inhibition is not sufficient to inhibit tumor growth and suggesting that the ability of Cuc Q to inhibit tumor growth is related to its anti-STAT3 activity. These studies further validate STAT3 as a drug discovery target and provide evidence that pharmacological agents that can selectively reduce the P-STAT3 levels in human cancer cells result in tumor apoptosis and growth inhibition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
21 February 2008
An Erratum to this paper has been published: https://doi.org/10.1038/sj.onc.1211028
References
Aoki Y, Feldman GM and Tosato G . (2003). Blood, 101, 1535–1542.
Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E and Smith PD . (2001). Int. J. Oncol., 19, 1155–1160.
Bharti AC, Donato N and Aggarwal BB . (2003). J. Immunol., 171, 3863–3871.
Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R and Sebti SM . (2003). Cancer Res., 63, 1270–1279.
Bowman T and Jove R . (1999). Cancer Control, 6, 615–619.
Cao X, Tay A, Guy GR and Tan YH . (1996). Mol. Cell. Biol., 16, 1595–1603.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R . (1999). Immunity, 10, 105–115.
Fernandes A, Hamburger AW and Gerwin BI . (1999). Int. J. Cancer, 83, 564–570.
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A and Jove R . (2001). Oncogene, 20, 2499–2513.
Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP and Jove R . (1997). Cell Growth Differ., 8, 1267–1276.
Hanahan D and Weinberg RA . (2000). Cell, 100, 57–70.
Horvath CM and Darnell JE . (1997). Curr. Opin. Cell Biol., 9, 233–239.
Ihle JN and Kerr IM . (1995). Trends Genet., 11, 69–74.
Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, Griffiths E, Krawczyk C, Richardson CD, Aitken K, Iscove N, Koretzky G, Johnson P, Liu P, Rothstein DM and Penninger JM . (2001). Nature, 409, 349–354.
Konnikova L, Kotecki M, Kruger MM and Cochran BH . (2003). BMC Cancer, 3, 23.
Lefebvre DC, Felberg J, Cross JL and Johnson P . (2003). Biochim. Biophys. Acta, 1650, 40–49.
Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki A, Schneider-Mergener J, Yoshimura A, Neel BG, Heinrich PC and Schaper F . (2003). J. Biol. Chem., 278, 661–671.
Lufei C, Ma J, Huang G, Zhang T, Novotny-Diermayr V, Ong CT and Cao X . (2003). EMBO J., 22, 1325–1335.
Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J and Jove R . (2002). Cancer Res., 62, 6659–6666.
Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, Salmeen A, Barford D and Tonks NK . (2001). J. Biol. Chem., 276, 47771–47774.
Ning ZQ, Li J and Arceci RJ . (2001). Blood, 97, 3559–3567.
Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H . (2002a). Oncogene, 21, 7001–7010.
Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R and Yu H . (1999). Cancer Res., 59, 5059–5063.
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H . (2002b). Oncogene, 21, 2000–2008.
Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV and Alkan S . (2003). Anticancer Res., 23, 2253–2260.
Schindler C and Darnell Jr JE . (1995). Annu. Rev. Biochem., 64, 621–651.
Shuai K, Halpern J, ten Hoeve J, Rao X and Sawyers CL . (1996). Oncogene, 13, 247–254.
Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ and Jove R . (2000). Oncogene, 19, 5419–5427.
Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S and Hiddemann W . (2002). Exp. Hematol., 30, 262–271.
Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD . (1998). Annu. Rev. Biochem., 67, 227–264.
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S and Jove R . (1999). Mol. Cell. Biol., 19, 7519–7528.
Turkson J and Jove R . (2000). Oncogene, 19, 6613–6626.
Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD and Jove R . (2004). Mol. Cancer Ther., 3, 261–269.
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD and Jove R . (2001). J. Biol. Chem., 276, 45443–45455.
Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D and Yu H . (2004). Nat. Med., 10, 48–54.
Wormald S and Hilton DJ . (2004). J. Biol. Chem., 279, 821–824.
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J and Jove R . (1995). Science, 269, 81–83.
Zhang T, Ma J and Cao X . (2003). Biochem. J., 376, 457–464.
Acknowledgements
We thank Drs Edward Sausville, Jill Johnson, George Johnson, Daniel Zaharevitz, Robert Schultz, and John Beutler from the NCI Developmental Therapeutics Program for providing us with the cucurbitacin compounds. We also thank the Pathology Core at the H Lee Moffitt Cancer Center and Research Institute. This work was supported by the National Cancer Institute Grant CA78038 (SMS).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, J., Blaskovich, M., Jove, R. et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24, 3236–3245 (2005). https://doi.org/10.1038/sj.onc.1208470
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208470
Keywords
This article is cited by
-
Apoptotic and antimetastatic effect of cucurbitacins in cancer: recent trends and advancement
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
Antitumor activity and mechanism of cucurbitacin B in A549/DDP cells
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
Diet-derived small molecules (nutraceuticals) inhibit cellular proliferation by interfering with key oncogenic pathways: an overview of experimental evidence in cancer chemoprevention
Biologia Futura (2022)
-
FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment
Investigational New Drugs (2021)
-
Use of cucurbitacins for lung cancer research and therapy
Cancer Chemotherapy and Pharmacology (2021)